Loading patent…
AssigneeActinium Pharmaceuticals, Inc.
InventorMark Berger
Estimating the term…
Provided are methods for treating acute myeloid leukemia that include administering a regimen of venetoclax and lintuzumab-Ac225, in which (a) the regimen includes a plurality of cycles, each cycle lasting from 28 to 60 days, (b) the regimen includes (i) orally administering venetoclax on days 1 and 2 of the first cycle at a ramp-up dosage, and thereafter orally administering 400 mg of venetoclax daily on days 3-21 of the first cycle and days 1-21 of each subsequent cycle, and (ii) intravenously administering lintuzumab-Ac225 on day 4, 5, 6 or 7 of each cycle at a dose of from 0.1 μCi/kg to 2.0 μCi/kg, and (c) the subject has a peripheral blast burden at or below 1,000 blast cells/μl. Also provided are related methods in which the regimen includes intravenously administering lintuzumab-Ac225 twice during each cycle.
A method for treating a human subject afflicted with acute myeloid leukemia comprising administering to the subject a regimen of venetoclax and lintuzumab-Ac225, wherein (a) the regimen comprises a plurality of cycles, each cycle lasting from 28 to 60 days, (b) the regimen comprises (i) orally administering venetoclax on days 1 and 2 of the first cycle at a ramp-up dosage, and thereafter orally administering 400 mg of venetoclax daily on days 3-21 of the first cycle and days 1-21 of each subsequent cycle, and (ii) intravenously administering lintuzumab-Ac225 on day 4, 5, or 6 of each cycle at a dose of from 0.1 μCi/kg to 2.0 μCi/kg;
A method for treating a human subject afflicted with acute myeloid leukemia comprising administering to the subject a regimen of venetoclax and lintuzumab-Ac225, wherein (a) the regimen comprises four cycles, each cycle lasting 28 days, (b) the regimen comprises (i) orally administering venetoclax at a dose of 100 mg and 200 mg, respectively, on days 1 and 2 of the first cycle, and thereafter orally administering 400 mg of venetoclax daily on days 3-21 of the first cycle and days 1-21 of each subsequent cycle, and (ii) intravenously administering lintuzumab-Ac225 on day 5 of each cycle at a dose of 0.25 μCi/kg, 0.5 μCi/kg, 1.0 μCi/kg, or 1.5 μCi/kg;
A method for treating a human subject afflicted with acute myeloid leukemia comprising administering to the subject a regimen of venetoclax and lintuzumab-Ac225, wherein (a) the regimen comprises a plurality of cycles, each cycle lasting from 28 to 60 days, (b) the regimen comprises (i) orally administering venetoclax on days 1 and 2 of the first cycle at a ramp-up dosage, and thereafter orally administering 400 mg of venetoclax daily on days 3-21 of the first cycle and days 1-21 of each subsequent cycle, and (ii) intravenously administering lintuzumab-Ac225 on day 4, 5, or 6 of each cycle at a dose of from 0.05 μCi/kg to 1.0 μCi/kg, and on day 18, 19, or 20 of each cycle at a dose of from 0.05 μCi/kg to 1.0 μCi/kg;
A method for treating a human subject afflicted with acute myeloid leukemia comprising administering to the subject a regimen of venetoclax and lintuzumab-Ac225, wherein (a) the regimen comprises four cycles, each cycle lasting 28 days, (b) the regimen comprises (i) orally administering venetoclax at a dose of 100 mg and 200 mg, respectively, on days 1 and 2 of the first cycle, and thereafter orally administering 400 mg of venetoclax daily on days 3-21 of the first cycle and days 1-21 of each subsequent cycle, and (ii) intravenously administering lintuzumab-Ac225 on day 5 of each cycle at a dose of 0.125 μCi/kg, 0.25 μCi/kg, 0.5 μCi/kg, or 0.75 μCi/kg, and on day 19 of each cycle at a dose of 0.125 μCi/kg, 0.25 μCi/kg, 0.5 μCi/kg, or 0.75 μCi/kg;
Dependencies are inferred from the claim text.